Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$113,782 Mln
Revenue (TTM)
$46,716 Mln
Net Profit (TTM)
$7,813 Mln
ROE
0.1 %
ROCE
8.3 %
P/E Ratio
20.1
P/B Ratio
1.3
Industry P/E
--
EV/EBITDA
8.5
Div. Yield
8.8 %
Debt to Equity
0.3
Book Value
$29.2
EPS
$3.2
Face value
--
Shares outstanding
2,406,138,970
CFO
€83,813.00 Mln
EBITDA
€107,491.00 Mln
Net Profit
€56,680.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sanofi ADS - ADR
| -1.5 | -1.9 | -1.5 | -13.9 | -4.3 | -0.7 | 1.7 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P 100
| -7.2 | -4.1 | -6.5 | 18.4 | 19.6 | 12.2 | 13.4 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Sanofi ADS - ADR
| 0.5 | -3.0 | 2.7 | -3.3 | 7.0 | 0.4 | 20.5 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus... influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. Sanofi has a strategic collaboration with miRecule, Inc. to facilitate the advancement of therapy DUX4, a genetic driver of debilitating muscular disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France. Address: 46, avenue de la Grande ArmEe, Paris, France, 75017 Read more
CEO & Director
Mr. Paul Hudson
CEO & Director
Mr. Paul Hudson
Headquarters
Paris
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Sanofi ADS - ADR is $47.73 (NASDAQ) as of 01-Apr-2026 16:00 EDT. Sanofi ADS - ADR has given a return of -4.28% in the last 3 years.
The P/E ratio of Sanofi ADS - ADR is 20.05 times as on 31-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
15.14
|
1.66
|
|
2024
|
21.75
|
1.56
|
|
2023
|
23.09
|
1.68
|
|
2022
|
14.51
|
1.62
|
|
2021
|
20.21
|
1.83
|
The 52-week high and low of Sanofi ADS - ADR are Rs 55.77 and Rs 43.32 as of 02-Apr-2026.
Sanofi ADS - ADR has a market capitalisation of $ 113,782 Mln as on 31-Mar-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Sanofi ADS - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.45
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.